Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4174794 · 1 trial · 2 indications
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| Part A: LY4174794 | EXPERIMENTAL | Participants will receive LY4174794 administered subcutaneously (SC). |
| Part B: LY4174794 | EXPERIMENTAL | Participants will receive LY4174794 administered SC. |
| Part A & B: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo administered SC. |
| Part C: LY4174794 | EXPERIMENTAL | Participants will receive LY4174794 administered intravenously (IV). |
| Name | Type | Description |
|---|---|---|
| LY4174794 | DRUG | Administered SC. |
| Placebo | DRUG | Administered SC. |
Inclusion Criteria: * Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease * Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m² * Have had a self-repo...
Top 20 of 35 competitors
LY4174794 is an investigational small-molecule drug being developed by Eli Lilly and Company for obesity and overweight. It is in Phase 1 clinical development and is not approved for any use. It is being studied in otherwise healthy adults with obesity or overweight.
LY4174794 is being studied as a treatment for obesity and overweight in adults who are otherwise healthy. The research is at the Phase 1 stage, so the drug remains investigational and has not been approved for weight management or any other indication.
LY4174794 is made by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the developer of the compound and is running the clinical program evaluating it in adults with obesity or overweight.
LY4174794 is in Phase 1 clinical development. It is an investigational small-molecule drug and is not FDA approved. The program consists of one active Phase 1 trial, which is currently recruiting participants.
LY4174794 is being studied in one Phase 1 trial, NCT07654972, titled A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy. The trial is recruiting 116 participants across the United States and Singapore, is randomized, double-blind, and placebo-controlled, and enrolls adults 18 years and older.